Study on related risk factors of pain in de novo Parkinson's disease patients

doi:10.3969/j.issn.1672-6731.2022.03.009

Abstract

Abstract: Objective To explore the risk factors of pain in de novo Parkinson's disease (PD) patients. Methods A total of 129 de novo PD patients collected from The Affiliated Brain Hospital of Nanjing Medical University from October 2018 to September 2021 were included. According to the Item-17 of the Unified Parkinson's Disease Rating Scale Ⅱ (UPDRSⅡ-17th), patients were classified as PD patients without pain (UPDRSⅡ-17th was 0, n=88) and PD patients with pain (UPDRSⅡ-17th ≥ 2, n=41). Mini-Mental State Examination (MMSE) and corrected Montreal Cognitive Assessment (corrected MoCA) were used to assess cognitive function. Meanwhile, Hamilton Depression Rating Scale-24 Items (HAMD-24) was used to assess the depression status and the UPDRSⅢ was used to assess the motor function. The modified version of Hoehn-Yahr staging was used to assess disease severity. The related risk factors of pain in PD patients were analyzed by univariate and multivariate forward Logistic regression. Results The incidence of pain in PD patients was 31.78% (41/129). Compared with PD without pain group, PD with pain group had lower scores in MMSE (Z=-2.389, P=0.017) and corrected MoCA (Z=-2.166, P=0.030), but higher scores in HAMD-24 (Z=-4.024, P=0.000), UPDRS Ⅲ (Z=-3.639, P=0.000) and Hoehn-Yahr staging grading (Z=-2.232, P=0.026). Further analysis of the differences between 2 groups in 7 domains of HAMD-24 showed PD with pain group had higher scores of the anxiety/somatization (Z=-3.707, P=0.000), mental disorder (Z=-2.519, P=0.012), retardation symptom (Z=-2.048, P=0.041), sleep disturbances (Z=-3.484, P=0.000) and despair symptom (Z=-3.069, P=0.002) than PD without pain group. Logistic regression analysis showed long duration (OR=1.354, 95%CI:1.013-1.809; P=0.041), high HAMD-24 score (OR=1.095, 95%CI:1.033-1.162; P=0.002) and high UPDRS Ⅲ score (OR=1.040, 95%CI:1.001-1. 082; P=0.046) were risk factors of pain in PD patients. Conclusions Pain in PD has a high incidence in de novo PD patients. Long duration, a depressed state and severe motor symptoms are main risk factors for the development of pain in PD patients.

Key words: Parkinson disease, Pain, Risk factors, Logistic models

摘要： 目的筛查初诊且未曾服药的帕金森病患者发生疼痛的危险因素。方法纳入2018年10月至2021年9月南京医科大学附属脑科医院收治的129例初诊帕金森病患者，根据统一帕金森病评价量表第二部分（UPDRSⅡ）第17项分为非疼痛组（评分为零，88例）和疼痛组（评分 ≥ 2，41例），采用简易智能状态检查量表（MMSE）和校正蒙特利尔认知评价量表（MoCA）评估患者认知功能，汉密尔顿抑郁量表24项（HAMD-24）评估患者抑郁症状，统一帕金森病评价量表第三部分（UPDRSⅢ）评估运动功能，Hoehn-Yahr分期改良版评估病情严重程度；单因素和多因素前进法Logistic回归分析筛查帕金森病患者发生疼痛的危险因素。结果 129例患者中共41例（31.78%）发生疼痛。与非疼痛患者（88例）相比，疼痛患者MMSE评分（Z=-2.389，P=0.017）和校正MoCA评分（Z=-2.166，P=0.030）较低；HAMD-24评分（Z=-4.024，P=0.000）及其焦虑/躯体化（Z=-3.707，P=0.000）、精神障碍（Z=-2.519，P=0.012）、迟缓症状（Z=-2.048，P=0.041）、睡眠障碍（Z=-3.484，P=0.000）和绝望症状（Z=-3.069，P=0.002）分评分，UPDRSⅢ评分（Z=-3.639，P=0.000）和Hoehn-Yahr分级（Z=-2.232，P=0.026）较高。Logistic回归分析显示，病程长（OR=1.354，95% CI：1.013~1.809；P=0.041）、HAMD-24评分高（OR=1.095，95% CI：1.033~1.162；P=0.002）和UPDRSⅢ评分高（OR=1.040，95% CI：1.001~1.082；P=0.046）是帕金森病患者发生疼痛的危险因素。结论初诊帕金森病患者疼痛发生率较高，病程长、抑郁症状严重和运动障碍严重是帕金森病患者发生疼痛的主要危险因素。

关键词: 帕金森病, 疼痛, 危险因素, Logistic模型

GUO Zhi-ying, LIU Wei-guo, SUN Yu, ZHENG Hui-fen, YANG Yu-xuan, ZHAO Ming-ming. Study on related risk factors of pain in de novo Parkinson's disease patients[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2022, 22(3): 173-178.

郭志颖, 刘卫国, 孙钰, 郑慧芬, 杨予萱, 赵名明. 初诊帕金森病患者疼痛相关危险因素分析[J]. 中国现代神经疾病杂志, 2022, 22(3): 173-178.

/ / Recommend / Download Citations

URL: http://journal11.magtechjournal.com/cjcnn/EN/10.3969/j.issn.1672-6731.2022.03.009

http://journal11.magtechjournal.com/cjcnn/EN/Y2022/V22/I3/173

References

[1] Hanagasi HA, Akat S, Gurvit H, Yazici J, Emre M. Pain is common in Parkinson's disease[J]. Clin Neurol Neurosurg, 2011, 113:11-13.
[2] Ford B. Pain in Parkinson's disease[J]. Mov Disord, 2010, 25 Suppl 1:98-103.
[3] Buhmann C, Kassubek J, Jost WH. Management of pain in Parkinson's disease[J]. J Parkinsons Dis, 2020, 10(s1):37-48.
[4] Buhmann C, Ip CW, Oehlwein C, Tönges L, Wolz M, Reichmann H, Kassubek J. Parkinson disease and pain:diagnostic and therapeutic approaches to a challenging non-motor symptom[J]. Fortschr Neurol Psychiatr, 2018, 86(S 01):48-58.
[5] Defazio G, Berardelli A, Fabbrini G, Martino D, Fincati E, Fiaschi A, Moretto G, Abbruzzese G, Marchese R, Bonuccelli U, Dotto PD, Barone P, Vivo ED, Albanese A, Antonini A, Canesi M, Lopiano L, Zibetti M, Nappi G, Martignoni E, Lamberti P, Tinazzi M. Pain as a nonmotor symptom of Parkinson disease[J]. Arch Neurol, 2008, 65:1191-1194.
[6] Leroi I, Overshott R, Byrne EJ, Daniel E, Burns A. Randomized controlled trial of memantine in dementia associated with Parkinson's disease[J]. Mov Disord, 2009, 24:1217-1221.
[7] Parkinson's Disease and Movement Disorders Group, Neurology Branch, Chinese Medical Association; Parkinson's Disease and Movement Disorders Specialty, Neurology Branch, Chinese Medical Doctor Association. Diagnostic criteria for Parkinson's disease in China (2016 edition)[J]. Zhonghua Shen Jing Ke Za Zhi, 2016, 49:268-271.[中华医学会神经病学分会帕金森病及运动障碍学组, 中国医师协会神经内科医师分会帕金森病及运动障碍专业. 中国帕金森病的诊断标准(2016版)[J]. 中华神经科杂志, 2016, 49:268-271.]
[8] Crum RM, Anthony JC, Bassett SS, Folstein MF. Population-based norms for the mini-mental state examination by age and educational level[J]. JAMA, 1993, 269:2386-2391.
[9] Dalrymple-Alford JC, MacAskill MR, Nakas CT, Livingston L, Graham C, Crucian GP, Melzer TR, Kirwan J, Keenan R, Wells S, Porter RJ, Watts R, Anderson TJ. The MoCA:well-suited screen for cognitive impairment in Parkinson disease[J]. Neurology, 2010, 75:1717-1725.
[10] Hamilton M. A rating scale for depression[J]. J Neurol Neurosurg Psychiatry, 1960, 23:56-62.
[11] Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease. The Unified Parkinson's Disease Rating Scale (UPDRS):status and recommendations[J]. Mov Disord, 2003, 18:738-750.
[12] Perez-Lloret S, Ciampi de Andrade D, Lyons KE, Rodríguez-Blázquez C, Chaudhuri KR, Deuschl G, Cruccu G, Sampaio C, Goetz CG, Schrag A, Martinez-Martin P, Stebbins G; Members of the MDS Committee on Rating Scales Development. Rating scales for pain in Parkinson's disease:critique and recommendations[J]. Mov Disord Clin Pract, 2016, 3:527-537.
[13] Kinugawa K, Mano T, Sugie K. Neuronal dynamics of pain in Parkinson's disease[J]. Brain Sci, 2021, 11:1224.
[14] Sun HH, Xiao PR. Analysis of risk factors on pain in PD patients[J]. Xian Dai Yi Xue Yu Jian Kang Yan Jiu (Dian Zi Ban), 2020, 4:109-110.[孙海华, 肖佩荣. PD患者疼痛的相关危险因素分析[J]. 现代医学与健康研究(电子版), 2020, 4:109-110.]
[15] DeLong MR. Primate models of movement disorders of basal ganglia origin[J]. Trends Neurosci, 1990, 13:281-285.
[16] Silverdale MA, Kobylecki C, Kass-Iliyya L, Martinez-Martin P, Lawton M, Cotterill S, Chaudhuri KR, Morris H, Baig F, Williams N, Hubbard L, Hu MT, Grosset DG; UK Parkinson's Pain Study Collaboration. A detailed clinical study of pain in 1957 participants with early/moderate Parkinson's disease[J]. Parkinsonism Relat Disord, 2018, 56:27-32.
[17] Lin XJ, Yu N, Lin XG, Zhang YF, Chen Y, Zhang K, Wang XS, Liu WG. A clinical survey of pain in Parkinson's disease in Eastern China[J]. Int Psychogeriatr, 2016, 28:283-289.
[18] Ehrt U, Larsen JP, Aarsland D. Pain and its relationship to depression in Parkinson disease[J]. Am J Geriatr Psychiatry, 2009, 17:269-275.
[19] Ozturk EA, Gundogdu I, Kocer B, Comoglu S, Cakci A. Chronic pain in Parkinson's disease:frequency, characteristics, independent factors, and relationship with health-related quality of life[J]. J Back Musculoskelet Rehabil, 2016.[Epub ahead of print]
[20] Grinberg LT, Rueb U, Alho AT, Heinsen H. Brainstem pathology and non-motor symptoms in PD[J]. J Neurol Sci, 2010, 289:81-88.
[21] Neugebauer V. Amygdala pain mechanisms[J]. Handb Exp Pharmacol, 2015, 227:261-284.
[22] Rukavina K, Leta V, Sportelli C, Buhidma Y, Duty S, Malcangio M, Ray Chaudhuri K. Pain in Parkinson's disease:new concepts in pathogenesis and treatment[J]. Curr Opin Neurol, 2019, 32:579-588.
[23] Juri C, Rodriguez-Oroz M, Obeso JA. The pathophysiological basis of sensory disturbances in Parkinson's disease[J]. J Neurol Sci, 2010, 289:60-65.
[24] Tong Q, Zhang L, Yuan Y, Jiang S, Zhang R, Xu Q, Ding J, Li D, Zhou X, Zhang K. Reduced plasma serotonin and 5-hydroxyindoleacetic acid levels in Parkinson's disease are associated with nonmotor symptoms[J]. Parkinsonism Relat Disord, 2015, 21:882-887.
[25] Rana AQ, Qureshi ARM, Shamli Oghli Y, Saqib Y, Mohammed B, Sarfraz Z, Rana R. Decreased sleep quality in Parkinson's patients is associated with higher anxiety and depression prevalence and severity, and correlates with pain intensity and quality[J]. Neurol Res, 2018, 40:696-701.
[26] Djaldetti R, Yust-Katz S, Kolianov V, Melamed E, Dabby R. The effect of duloxetine on primary pain symptoms in Parkinson disease[J]. Clin Neuropharmacol, 2007, 30:201-205.
[27] Defazio G, Antonini A, Tinazzi M, Gigante AF, Pietracupa S, Pellicciari R, Bloise M, Bacchin R, Marcante A, Fabbrini G, Berardelli A. Relationship between pain and motor and non-motor symptoms in Parkinson's disease[J]. Eur J Neurol, 2017, 24:974-980.
[28] Vila-Chã N, Cavaco S, Mendes A, Gonçalves A, Moreira I, Fernandes J, Damásio J, Azevedo LF, Castro-Lopes J. Unveiling the relationship between central parkinsonian pain and motor symptoms in Parkinson's disease[J]. Eur J Pain, 2019, 23:1475-1485.
[29] Fu YT, Mao CJ, Ma LJ, Zhang HJ, Wang Y, Li J, Huang JY, Liu JY, Liu CF. Pain correlates with sleep disturbances in Parkinson's disease patients[J]. Pain Pract, 2018, 18:29-37.

Please choose a citation manager

Content to export